Penumbra, Inc. (NYSE:PEN) EVP Johanna Roberts Sells 600 Shares

Penumbra, Inc. (NYSE:PEN - Get Free Report) EVP Johanna Roberts sold 600 shares of the stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $258.17, for a total value of $154,902.00. Following the completion of the sale, the executive vice president now owns 64,714 shares in the company, valued at approximately $16,707,213.38. The trade was a 0.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Johanna Roberts also recently made the following trade(s):

• On Monday, May 12th, Johanna Roberts sold 900 shares of Penumbra stock. The stock was sold at an average price of $298.55, for a total value of $268,695.00.
• On Thursday, April 24th, Johanna Roberts sold 600 shares of Penumbra stock. The stock was sold at an average price of $300.01, for a total value of $180,006.00.
• On Tuesday, April 1st, Johanna Roberts sold 600 shares of Penumbra stock. The stock was sold at an average price of $269.11, for a total value of $161,466.00.

Penumbra Stock Performance

Shares of NYSE PEN traded down $2.35 during trading on Wednesday, reaching $255.01. 521,337 shares of the company traded hands, compared to its average volume of 449,043. The firm's fifty day simple moving average is $277.57 and its 200 day simple moving average is $266.53. The stock has a market cap of $9.88 billion, a P/E ratio of 750.03, a PEG ratio of 2.83 and a beta of 0.53. Penumbra, Inc. has a 12-month low of $148.00 and a 12-month high of $310.00. The company has a current ratio of 6.01, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02.

Penumbra (NYSE:PEN - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The company reported $0.83 earnings per share for the quarter, beating analysts' consensus estimates of $0.66 by $0.17. The business had revenue of $324.14 million during the quarter, compared to analyst estimates of $315.72 million. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The company's revenue was up 16.3% on a year-over-year basis. During the same quarter last year, the business posted $0.41 EPS. As a group, research analysts anticipate that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Penumbra

A number of institutional investors have recently modified their holdings of the business. Quadrant Capital Group LLC grew its position in shares of Penumbra by 6.6% during the 4th quarter. Quadrant Capital Group LLC now owns 632 shares of the company's stock valued at $150,000 after acquiring an additional 39 shares during the period. Baker Avenue Asset Management LP grew its position in shares of Penumbra by 1.6% during the 4th quarter. Baker Avenue Asset Management LP now owns 3,330 shares of the company's stock valued at $791,000 after acquiring an additional 53 shares during the period. Fifth Third Bancorp grew its position in shares of Penumbra by 16.4% during the 1st quarter. Fifth Third Bancorp now owns 404 shares of the company's stock valued at $108,000 after acquiring an additional 57 shares during the period. CIBC Asset Management Inc grew its position in shares of Penumbra by 5.4% during the 4th quarter. CIBC Asset Management Inc now owns 1,183 shares of the company's stock valued at $281,000 after acquiring an additional 61 shares during the period. Finally, Corient Private Wealth LLC grew its position in shares of Penumbra by 3.7% during the 4th quarter. Corient Private Wealth LLC now owns 1,695 shares of the company's stock valued at $403,000 after acquiring an additional 61 shares during the period. 88.88% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently issued reports on PEN shares. Needham & Company LLC reissued a "hold" rating on shares of Penumbra in a research note on Wednesday, February 19th. Royal Bank of Canada increased their price objective on Penumbra from $315.00 to $330.00 and gave the stock an "outperform" rating in a research note on Thursday, April 24th. Bank of America initiated coverage on Penumbra in a research note on Friday, March 14th. They issued a "buy" rating and a $320.00 price objective on the stock. Morgan Stanley increased their target price on Penumbra from $240.00 to $260.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 19th. Finally, Robert W. Baird raised their price objective on Penumbra from $316.00 to $325.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. Three equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Penumbra has an average rating of "Moderate Buy" and a consensus price target of $302.40.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.